Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Account Payables (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Change in Account Payables for 11 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 384.61% to $7.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.0 million, a 11.96% decrease, with the full-year FY2025 number at $6.0 million, down 11.96% from a year prior.
  • Change in Account Payables was $7.0 million for Q4 2025 at Intellia Therapeutics, up from $3.5 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $7.0 million in Q4 2025 to a low of -$7.7 million in Q3 2023.
  • A 5-year average of $562700.0 and a median of $743000.0 in 2021 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 2152.63% in 2023; the steepest drop was 374.51% in 2023.
  • Intellia Therapeutics' Change in Account Payables stood at $2.4 million in 2021, then crashed by 68.74% to $750000.0 in 2022, then skyrocketed by 425.47% to $3.9 million in 2023, then plummeted by 63.56% to $1.4 million in 2024, then surged by 384.61% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Change in Account Payables are $7.0 million (Q4 2025), $3.5 million (Q3 2025), and -$2.6 million (Q2 2025).